Physician profile
Scott D Baker
NPI 1861504318
$14,813.35
in general payments reported to CMS, 2019-2025
48 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 81% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,523 · 2020: $1,210 · 2021: $2,181 · 2022: $2,997 · 2023: $2,538 · 2024: $2,281 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,706 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,705.51 |
| Education | $196.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $3,402.70 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $1,713.47 | 2019-2025 | Erleada, Akeega, Abiraterone Acetate |
| Astellas Pharma US INC | $1,566.94 | 2019-2025 | Xtandi, Myrbetriq |
| Myriad Genetic Laboratories, INC. | $850.42 | 2021-2025 | Prolaris, Myrisk |
| Pfizer INC. | $617.58 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $585.10 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Sumitomo Pharma America, INC. | $561.98 | 2023-2025 | Gemtesa, Orgovyx |
| Blue Earth Diagnostics | $497.21 | 2019-2024 | |
| Abbvie INC. | $465.85 | 2019-2025 | Botox, Lupron Depot |
| Urovant Sciences INC | $322.61 | 2021-2022 | |
| Accord Healthcare, INC. | $293.81 | 2022-2023 | |
| Endo Pharmaceuticals INC. | $288.74 | 2019-2024 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $282.92 | 2021-2025 | Jelmyto |
| Olympus America INC. | $256.15 | 2021-2025 | Itind System, Oes Cystonephrofiberscope |
| Bayer Healthcare Pharmaceuticals INC. | $223.77 | 2019-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $196.04 | 2023-2024 | Urolift |
| Progenics Pharmaceuticals, INC. | $191.44 | 2022-2025 | |
| Myovant Sciences INC. | $190.85 | 2021-2022 | |
| Neotract INC. | $188.99 | 2019-2020 | |
| Antares Pharma, INC. | $172.24 | 2019-2024 | Xyosted |
| Boston Scientific Corporation | $162.49 | 2019-2025 | Wavewriter Alpha Prime 16, Varithena Administration Pack, Rezum Generator |
| Allergan, INC. | $149.06 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $146.21 | 2021-2025 | Lynparza, Imfinzi |
| Endo USA, INC. | $137.25 | 2024-2025 | Xiaflex |
| Conmed Corporation | $124.99 | 2024 | Airseal |
| Tolmar, INC. | $118.82 | 2023-2025 | Eligard, Jatenzo |
| Ferring Pharmaceuticals INC. | $118.36 | 2019-2025 | Adstiladrin |
| Terumo Medical Corporation | $113.17 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $110.45 | 2019-2022 | |
| Procept Biorobotics Corporation | $110.16 | 2019 | |
| Acerus Pharmaceuticals Corporation | $94.36 | 2020-2022 | |
| Amgen INC. | $73.36 | 2019-2021 | |
| Clarus Therapeutics INC. | $73.28 | 2021 | |
| Novartis Pharmaceuticals Corporation | $56.19 | 2024-2025 | |
| Verity Pharmaceuticals INC. | $56.06 | 2025 | Trelstar |
| Travere Therapeutics, INC. | $49.63 | 2019-2021 | |
| Halozyme INC | $34.97 | 2023 | |
| Alnylam Pharmaceuticals INC. | $32.72 | 2025 | Givlaari |
| Civco Medical Instruments | $30.44 | 2024-2025 | |
| Foundation Medicine, INC. | $29.60 | 2023 | Foundationone Liquid Cdx |
| Baxter Healthcare | $19.98 | 2021 | |
| Cycle Pharmaceuticals INC | $19.91 | 2025 | Venxxiva |
| Baudax Bio INC. | $17.56 | 2020 | |
| Telix Pharmaceuticals | $16.17 | 2022 | |
| Mission Pharmacal Company | $13.90 | 2023 | Uribel |
| Photocure INC | $12.30 | 2021 | |
| Avadel Specialty Pharmaceuticals, LLC | $11.78 | 2019 | |
| Ambu INC. | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.